CMS would set when Medicare’s rare-drug clock starts

Rare-disease drugs are getting a new Medicare clock. In Washington, the Centers for Medicare & Medicaid Services, or CMS, is proposing a rule that would help decide when orphan-drug protection starts to run out and when those medicines can move closer to Medicare price talks.

The change matters because the timing is not a footnote. For drugs that have relied on the orphan-drug exclusion, the day CMS chooses becomes the starting point for measuring the 7-year and 11-year periods that control how long the protection lasts.

When the clock starts

The proposal follows a change in the Working Families Tax Cut. Section 71203(a)(2) amended the orphan-drug exclusion requirements, and section 71203(a)(3) added a new rule for former orphan drugs, the medicines that once qualified for the exclusion but no longer do.

That new language puts the start date at the center of the policy. CMS would identify the day from which the 7- and 11-year periods are measured for former orphan drugs, giving the agency a single reference point for when those drugs remain outside the negotiation track and when they do not.

Why the date matters

For manufacturers, the clock determines how long a rare-disease drug can keep its shield before Medicare price talks can begin. For Medicare beneficiaries, it helps shape when a drug may enter the pricing system that can affect access and out-of-pocket costs.

For Medicare Part D plans and CMS, the date is the practical line between protection and negotiation. It tells the program when orphan-drug status ends, when former-orphan status begins to matter, and which day should be used to measure the periods that follow.